U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H13N4O2S.Na
Molecular Weight 300.312
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFISOMIDINE SODIUM

SMILES

[Na+].CC1=NC(C)=NC([N-]S(=O)(=O)C2=CC=C(N)C=C2)=C1

InChI

InChIKey=XTXYCJOBMKKQOW-UHFFFAOYSA-N
InChI=1S/C12H13N4O2S.Na/c1-8-7-12(15-9(2)14-8)16-19(17,18)11-5-3-10(13)4-6-11;/h3-7H,13H2,1-2H3;/q-1;+1

HIDE SMILES / InChI

Molecular Formula C12H14N4O2S
Molecular Weight 278.33
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sulfisomidine (INN), also known as sulphasomidine (BAN until 2003), is a sulfonamide antibacterial. It’s used in the treatment, control, prevention, and improvement of the following conditions and symptoms: Lower urinary tract infections; Meningococcal meningitis; Streptococcal pharyngitis; Gum infection; Bacillary dysentery.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Unknown

Approved Use

Unknown
Curative
Unknown

Approved Use

Unknown
Curative
Unknown

Approved Use

Unknown
Curative
Unknown

Approved Use

Unknown
Curative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.
1995 Aug
[Drugs and breastfeeding].
2002 Apr-Jun
Identification of the 'wrong' active pharmaceutical ingredient in a counterfeit Halfan drug product using accurate mass electrospray ionisation mass spectrometry, accurate mass tandem mass spectrometry and liquid chromatography/mass spectrometry.
2003
In-vitro antifungal activities of sulfa drugs against clinical isolates of Aspergillus and Cryptococcus species.
2007
Patents

Sample Use Guides

2 g twice daily
Route of Administration: Oral
In Vitro Use Guide
The monotherapy of S suis infections with sulfonamides (SULFISOMIDINE was one of them) should not be encouraged because the MIC50 of all sulfonamides investigated was greater than 32 micrograms/ml. The MIC50 of the sulfonamides against B bronchiseptica ranged from 0.5 to 8 micrograms/ml, against P multocida from 2 to 32 micrograms/ml, and against H pleuropneumoniae from 8 to 64 micrograms/ml.
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:36:20 UTC 2023
Edited
by admin
on Sat Dec 16 01:36:20 UTC 2023
Record UNII
296707F7DU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFISOMIDINE SODIUM
WHO-DD  
Common Name English
SULFISOMIDINE, SODIUM
Common Name English
Sulfisomidine sodium [WHO-DD]
Common Name English
SULFISOMIDINE SODIUM [JAN]
Common Name English
Code System Code Type Description
SMS_ID
100000142305
Created by admin on Sat Dec 16 01:36:20 UTC 2023 , Edited by admin on Sat Dec 16 01:36:20 UTC 2023
PRIMARY
ChEMBL
CHEMBL485696
Created by admin on Sat Dec 16 01:36:20 UTC 2023 , Edited by admin on Sat Dec 16 01:36:20 UTC 2023
PRIMARY
CAS
2462-17-1
Created by admin on Sat Dec 16 01:36:20 UTC 2023 , Edited by admin on Sat Dec 16 01:36:20 UTC 2023
PRIMARY
PUBCHEM
3543157
Created by admin on Sat Dec 16 01:36:20 UTC 2023 , Edited by admin on Sat Dec 16 01:36:20 UTC 2023
PRIMARY
EVMPD
SUB116492
Created by admin on Sat Dec 16 01:36:20 UTC 2023 , Edited by admin on Sat Dec 16 01:36:20 UTC 2023
PRIMARY
FDA UNII
296707F7DU
Created by admin on Sat Dec 16 01:36:20 UTC 2023 , Edited by admin on Sat Dec 16 01:36:20 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE